118 related articles for article (PubMed ID: 7853204)
1. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
[TBL] [Abstract][Full Text] [Related]
2. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
3. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
[TBL] [Abstract][Full Text] [Related]
4. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
5. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
7. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.
Goulet M; Morissette M; Calon F; Blanchet PJ; Falardeau P; Bédard PJ; Di Paolo T
Neuroscience; 1997 Jul; 79(2):497-507. PubMed ID: 9200732
[TBL] [Abstract][Full Text] [Related]
8. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
10. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
11. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Blanchet PJ; Gomez-Mancilla B; Bédard PJ
J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
[TBL] [Abstract][Full Text] [Related]
12. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
13. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.
Stephenson DT; Meglasson MD; Connell MA; Childs MA; Hajos-Korcsok E; Emborg ME
J Pharmacol Exp Ther; 2005 Sep; 314(3):1257-66. PubMed ID: 15980058
[TBL] [Abstract][Full Text] [Related]
14. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Gomez-Mancilla B; Bédard PJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
[TBL] [Abstract][Full Text] [Related]
15. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
16. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
17. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
[TBL] [Abstract][Full Text] [Related]
19. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
[No Abstract] [Full Text] [Related]
20. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
